CAS
PCRX icon

Coppell Advisory Solutions’s Pacira BioSciences PCRX Stock Holding History

Coppell Advisory Solutions’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58
Closed -$1.66K – 1941
2024
Q2 		$1.66K Buy
+58
New +$1.65K ﹤0.01% 1411

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Coppell Advisory Solutions's PCRX Position: Q3 2024 in Review

Coppell Advisory Solutions sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 58 shares — an estimated $1.66K sold.

Coppell Advisory Solutions first reported a position in PCRX in Q2 2024 and held it in 1 quarter. The position peaked at $1.66K in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Coppell Advisory Solutions reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Coppell Advisory Solutions sold 58 Pacira BioSciences shares in Q3 2024, an estimated $1.66K.
  • Coppell Advisory Solutions first reported a position in Pacira BioSciences in Q2 2024 and held it in 1 quarter.
  • Coppell Advisory Solutions's Pacira BioSciences position peaked at $1.66K in Q2 2024.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Coppell Advisory Solutions's 13F filing for Q3 2024, filed 14 Nov 2024.